ReviewDisease markers2013
Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.
Review in Disease markers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- The Emerging Lipid Risk: Lipoprotein(a).Korean circulation journal · 2026Review
- Lipoprotein(a): A Novel Risk Factor for Heart Failure and Biomarker of Prognosis? From Pathophysiology to Clinical Practice.Cardiac failure review · 2026Review
- Lowering of Lipoprotein(a) with Olpasiran.Cardiovascular & hematological disorders drug targets · 2026Review
- Novel lipid profiles and atherosclerotic cardiovascular disease risk: insights from a latent profile analysis.Lipids in health and disease · 2025Article
- Lipoprotein(a) and Its Role in Peripheral Arterial Disease: A Narrative Review.Vascular health and risk management · 2025Review
- Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review.International journal of molecular sciences · 2024Review
- Lipoprotein(a): Just an Innocent Bystander in Arterial Hypertension?International journal of molecular sciences · 2023Review
- High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine.Frontiers in cardiovascular medicine · 2023Review
- Familial Hypercholesterolemia and Lipoprotein(a): A Gordian Knot in Cardiovascular Prevention.Metabolites · 2022Review
- Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction.ESC heart failure · 2022Observational
- The Predictive Value of Lp(a) for Adverse Cardiovascular Event in ACS Patients With an Achieved LDL-C Target at Follow Up After PCI.Journal of cardiovascular translational research · 2022Article
- Predictive effect of different blood lipid parameters combined with carotid intima-media thickness on coronary artery disease.Frontiers in cardiovascular medicine · 2022Article
- Association between lipoprotein (a) and heart failure with reduced ejection fraction development.Journal of clinical laboratory analysis · 2022Article
- The association of lipoprotein(a) and intraplaque neovascularization in patients with carotid stenosis: a retrospective study.BMC cardiovascular disorders · 2021Observational
- Serum lipoprotein(a) and risk of periprocedural myocardial injury in patients undergoing percutaneous coronary intervention.Clinical cardiology · 2020Article
- Lipoprotein (a) as a residual risk factor for atherosclerotic renal artery stenosis in hypertensive patients: a hospital-based cross-sectional study.Lipids in health and disease · 2020Article
- Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry.Lipids in health and disease · 2020Article
- Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.Journal of lipids · 2020Review
- Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention.Archives of medical science : AMS · 2019Article
- Risk factors of thromboembolism in nonvalvular atrial fibrillation patients with low CHA2DS2-VASc score.Medicine · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerotic cardiovascular diseases (CVD) are still the leading cause of morbidity and mortality worldwide, although optimal medical therapy has been prescribed for primary and secondary preventions. Residual cardiovascular risk for some population groups is still considerably high although target low density lipoprotein-cholesterol (LDL-C) level has been achieved. During the past few decades, compelling pieces of evidence from clinical trials and meta-analyses consistently illustrate that lipoprotein(a) (Lp(a)) is a significant risk factor for atherosclerosis and CVD due to its proatherogenic and prothrombotic features. However, the lack of effective medication for Lp(a) reduction significantly hampers randomized, prospective, and controlled trials conducting. Based on previous findings, for patients with LDL-C in normal range, Lp(a) may be a useful marker for identifying and evaluating the residual cardiovascular risk, and aggressively lowering LDL-C level than current guidelines' recommendation may be reasonable for patients with particularly high Lp(a) level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.